Tscan Therapeutics Inc   (TCRX)
Other Ticker:  
Price: $6.7900 $0.03 0.444%
Day's High: $7.05 Week Perf: -8.37 %
Day's Low: $ 6.66 30 Day Perf: 36.35 %
Volume (M): 124 52 Wk High: $ 7.87
Volume (M$): $ 840 52 Wk Avg: $3.55
Open: $6.85 52 Wk Low: $1.62

 Market Capitalization (Millions $) 644
 Shares Outstanding (Millions) 95
 Employees -
 Revenues (TTM) (Millions $) 17
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 4

Tscan Therapeutics Inc
Tscan Therapeutics Inc. is a biotechnology company that specializes in the field of immunotherapy. The company focuses on developing and commercializing T cell receptor (TCR) engineered T cell therapies for the treatment of various types of cancer. TCRs are proteins found on the surface of T cells that recognize and bind to specific targets on cancer cells.

Tscan Therapeutics uses its proprietary TCR-engineering technology to modify T cells, enhancing their ability to recognize and eliminate cancer cells. The company's approach aims to leverage the natural power of the immune system to selectively target and destroy cancer cells while sparing healthy cells.

The company's research and development efforts are centered around identifying novel TCRs, engineering T cells with these receptors, and conducting preclinical and clinical studies to assess the safety and efficacy of their therapies. Tscan Therapeutics has also entered into collaborations and partnerships with other companies and academic institutions to strengthen its research capabilities and accelerate the development of its pipeline.

Overall, Tscan Therapeutics Inc. aims to revolutionize cancer treatment by harnessing the potential of T cell immunotherapies to offer more effective and targeted therapies for patients.

   Company Address: 830 Winter Street Waltham 2451 MA
   Company Phone Number: 399-9500   Stock Exchange / Ticker: NASDAQ TCRX
   TCRX is expected to report next financial results on March 07, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Catalyzing a Paradigm Shift: TScan Therapeutics' TSC-100 and TSC-101 Propelling Patients to Relapse-Free Remission and Complete Donor Chimerism

Published Mon, Feb 26 2024 12:00 PM UTC

is pleased to report on the highly promising and groundbreaking Phase 1 clinical results presented by TScan Therapeutics at the prestigious 2024 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR). These results showcase the company's innovative therapies, TSC-100...

Clinical Study

TScan Therapeutics to Present Promising Results of TSC-100 and TSC-101 in the Treatment of Heme Malignancies at Prestigious Medical Meetings and Host Virtual KOL Event for Discussion

Published Thu, Jan 18 2024 12:00 PM UTC

TScan Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer patients, is set to make groundbreaking strides in the treatment of heme malignancies. The company recently announced that it has been awarded the Best Abstracts Award and will be delivering an oral presentatio...

Financing Agreement

TScan Therapeutics Inc: Promising Clinical Data and Robust Financial Performance Drive 2024 Clinical Plans and Progress

Published Thu, Jan 4 2024 12:01 PM UTC

TScan Therapeutics: Positive Initial Data from Phase 1 Heme Program at ASH Annual Meeting
TScan Therapeutics Inc recently reported positive initial data from its Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting. The company's presentation at the conference showcased promising results, generating excitement and anticipation for the futu...

Clinical Study

TScan Therapeutics? TSC-100 and TSC-101: Transforming Hematological Disease Treatment, Clinical Trial Results Reveal No Relapses in Treatment Arm

Published Sat, Dec 9 2023 5:00 PM UTC

The highly anticipated phase 1 clinical trial results for TScan Therapeutics' experimental treatments, TSC-100 and TSC-101, were recently presented at the 65th American Society of Hematology Annual Meeting and Exposition. The findings exhibited unprecedented success in preventing relapses and minimizing the need for further clinical intervention.
Outline of Fac...

Clinical Study

TScan Therapeutics Presents Game-Changing Cancer Therapies: Unveiling Remarkable Phase 1 Trial Results at Virtual KOL Event

Published Mon, Dec 4 2023 9:05 PM UTC

TScan Therapeutics, a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer treatment, has announced its plans to host a virtual key opinion leader (KOL) event on December 11th. This event aims to discuss the key findings and highlights from TScan's recent poster presentation at the...


Tscan Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com